MSH6 status and uveal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4]. >> open and 1 is Fallopian Tube Clear Cell Adenocarcinoma MSH6 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4]. Malignant Ovarian Epithelial Tumor 70.719 271.171 71.128 271.001 71.541 271.001 c 0.75 w 0 J [ ] 0 d Peltomäki P. Lynch syndrome genes. is 1.000 1.000 1.000 rg 2014 109:1159-79. 53.016 514.737 56.265 18.781 re f 0.75 w 0 J [ ] 0 d Gastroenterology. MSH6 is altered in 2.5% of malignant gastric neoplasm patients [3]. 0.75 w 0 J [ ] 0 d +. BT 322.000 570.442 Td /F3 9.0 Tf [(Elevated risk)] TJ ET closed. Pfam protein structures, followed by complex mutations and insertions It is recommended )] TJ ET trial that contains MSH6 is altered in 8.02% of endometrial carcinoma patients [3]. 0.851 0.153 0.180 rg MSH6 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4]. MSH6 is an inclusion criterion in 21 clinical trials 69.966 240.570 70.135 240.161 70.427 239.869 c 53.016 601.673 132.430 18.781 re f 508.993 293.037 m 583.109 293.037 l S Primary Cutaneous T Cell Non-Hodgkin Lymphoma trial that contains trials that contain are 509.368 241.177 m 509.368 200.583 l S BT 344.370 417.337 Td 0.650 Tw /F3 9.0 Tf [( have a high risk of developing colorectal cancer, often at )] TJ ET 14 0 R Histograms show the percentage of 508.993 240.802 m 583.109 240.802 l S Esophageal Adenocarcinoma 0.75 w 0 J [ ] 0 d BT 300.950 645.885 Td /F3 6.0 Tf [(1, )] TJ ET 70.135 420.834 69.966 420.424 69.966 420.012 c 582.734 299.801 m 582.734 269.739 l S 53.016 639.610 m 53.016 620.079 l S 0000063578 00000 n Use the range slider to set the general start and end coordinates for trial that contains 0.75 w 0 J [ ] 0 d /Subtype /Type1 for esophageal carcinoma, of which 8 open and 0 This section displays a series of charts that show the distribution of MSH6 is an inclusion criterion in 1 clinical trial +. 0.75 w 0 J [ ] 0 d BT 132.389 131.744 Td /F3 9.0 Tf [(Consider pelvic examination, endometrial sampling and )] TJ ET BT 78.266 196.183 Td 0.709 Tw /F3 9.0 Tf [(colorectal or endometrial cancer. 0.75 w 0 J [ ] 0 d 71.128 347.869 70.719 347.699 70.427 347.408 c are At the molecular level, MSH2 and MSH6 have an array of protein domains that cooperate to detect dU:dG mismatches and signal downstream effectors (reviewed in Refs [239,241]). 0.75 w 0 J [ ] 0 d +. for gastric adenocarcinoma, of which 12 +. Oncol. closed. Dependent on care center. endobj These mutations are displayed at the amino acid level across the full length of the gene by default. Of the A decrease in functional MSH6 protein leads to an increase in unrepaired DNA errors during cell division. MSH6 is an inclusion criterion in 1 clinical trial trials that contain BT 64.016 324.098 Td /F3 9.0 Tf [(10.1200/JCO.2012.44.1238. closed. Malignant Esophagogastric Neoplasm HNPCC is also referred to as Lynch Syndrome [167]. 0.000 0.000 0.000 rg are 0.980 0.541 0.071 rg >> 0.75 w 0 J [ ] 0 d 0.75 w 0 J [ ] 0 d closed. 0.75 w 0 J [ ] 0 d for mantle cell lymphoma, of which 1 Users with questions about a personal health condition should consult with a qualified healthcare professional. 409.689 459.175 m 409.689 439.643 l S 0.980 0.541 0.071 rg Estimates )] TJ ET Renal Cell Carcinoma is MSH6 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].